|
Shares jump as Array BioPharma reports positive results for asthma drug
The Pharma Letter US biotech firm Array BioPharma (Nasdaq: ARRY) saw its shares jump as it announced that its drug candidate for mild to moderate persistent allergic asthma, ARRY-502, an oral CRTh2 antagonist, met all primary and secondary endpoints. The company said … |
View full post on asthma – Google News